ProtoKinetix files patent extension for small AAGP molecules

By Elaine Rigoli

Tampa, Fla., May 8 - ProtoKinetix, Inc. has filed patent extensions to include new dimensions of the AAGP family of molecules following the recent development of a smaller AAGP molecule, GCD-5-A, which has demonstrated improved effectiveness over previously tested larger AAGP molecules.

Using only 5 mg/ml of the GCD-5-A molecule, skin cells stressed with two hours of UV-C radiation were preserved to almost 100% viability for six days while all the untreated cells were dead, according to a news release.

This compares to 64% viability after 67 hours for skin cells protected with 15 mg/ml of the original larger AAGP monomer stressed with the same level of UV-C radiation, the release said.

ProtoKinetix is a Vancouver, B.C.-based biotechnical company that develops synthetic antifreeze glycoproteins for human and veterinary medicine, the biotechnology and cosmetic industries and as a food additive.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.